Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2025

Conditions

NSCLC Associated With Leptomeningeal Metastases

Interventions

DRUG

Tislelizumab, pemetrexed

Drug 1: Tislelizumab 50 mg; Drug 2: pemetrexed 20mg. intrathecal injection therapy

All Listed Sponsors

lead

West China Hospital

OTHER